We used the ground-truth class labels to evaluate the clustering results.
Using QDs as drug models and imaging labels to evaluate nano-particle formulations incorporating both hydrophilic and hydrophobic drugs and imaging agents is developed.
SubsequenTwo, thexperimentss less prone to distrareion in conductedcclusion or similarito bevaluateehicles.
Furthermore, we also apply a non-prefractionation quantitative phosphoproteomic approach using mTRAQ labeling to evaluate the expression of specific phosphoproteins during pregnancy comparison with non-pregnancy.
Since the true modified amino acids are predefined, we can use them as labels to evaluate the performance of the algorithms.
For the system calibration (learning features to predict labels), DeepDive holds out a test set from the training labels to evaluate DeepDive's predictions based on the input data.
Filtering methods apply knowledge of the class labels to evaluate the discrimination power either of individual genes (univariate) or collections of genes (multivariate), based on criteria such as signal-to-noise ratio, correlation measures, and mutual information, before classifier training.
Using the medoids learned from this cohort, we then clustered a second independent cohort of septic patients, and used the resulting class labels to evaluate differences in clinical parameters, as well as the expression of relevant pharmacogenes.
After an additional 24 hr, cells were immunofluorescently labeled to evaluate coincident localization with HA-Vangl2 and EEA1 (A )–(C ), HA-Vangl2 and Rab7 (D )–(F ) and HA-Vangl2 and Rab11 (G )–(I ).
After an additional 24 hr, cells were immunofluorescently labeled to evaluate coincident localization with Golgin 97 and GM130 (A – C ), HA-Vangl2 and GM130 (D – F ) and HA-Vangl2 and Golgin 97 (G – I ).
